Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Filings indexed 1,245 across all filing types
Latest filing 2023-08-03 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copies of newspaper advertisement ....
Regulatory Filings
2023-08-03 English
Outcome of Board Meeting
Regulatory Filings
2023-08-01 English
Financial Result Updates
Regulatory Filings
2023-08-01 English
We would like to inform you that the Board Meeting of the Company was held today i.e. Tuesday, August 01, 2023, at the registered office of the Company. In pursuant to Regulation 30 and ....
Regulatory Filings
2023-08-01 English
Board Meeting — BLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 01-Aug-2023 to consider and approve the Quarterly Unaudited Financial results of the Company for t…
Regulatory Filings
2023-07-28 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the allotment of shares under an Employee Stock Options Plan (ESOP). It details the number of shares allotted, the increase in issued share capital, and compliance with SEBI regulations. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The document is an announcement of a capital change due to share allotment under ESOP. The document length is 4492 characters, which is relatively short and focused on the share allotment event. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA).
2023-07-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.